What is it used for?
Kinpeygo contains budesonide in a formulation intended for primary IgA nephropathy in adults. EMA describes use when protein loss in urine is at least 1 g/day, or the urine protein-to-creatinine ratio is at least 0.8 g/g. Kidney assessment determines whether the indication applies.Kinpeygo contains budesonide in a formulation intended for primary IgA nephropathy in adults. EMA describes use when protein loss in urine is at least 1 g/day, or the urine protein-to-creatinine ratio is at least 0.8 g/g. Kidney assessment determines whether the indication applies.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- budesonidebudesonide
- Form and strength
- Modified-release hard capsules containing 4 mg budesonide. This formulation is not interchangeable with every other budesonide product.Modified-release hard capsules containing 4 mg budesonide. This formulation is not interchangeable with every other budesonide product.
- Manufacturer / applicant
- STADA Arzneimittel AGSTADA Arzneimittel AG
Modified-release hard capsules containing 4 mg budesonide. This formulation is not interchangeable with every other budesonide product.Modified-release hard capsules containing 4 mg budesonide. This formulation is not interchangeable with every other budesonide product.
Safety and clinical review
Severe liver impairment is a contraindication in the EU information. The clinician should also consider infection risk, corticosteroid effects and interactions.Severe liver impairment is a contraindication in the EU information. The clinician should also consider infection risk, corticosteroid effects and interactions.
- Severe liver impairmentSevere liver impairment
- Infections and corticosteroid effectsInfections and corticosteroid effects
- Other medicinesOther medicines
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Kinpeygo used for?
Kinpeygo contains budesonide in a formulation intended for primary IgA nephropathy in adults. EMA describes use when protein loss in urine is at least 1 g/day, or the urine protein-to-creatinine ratio is at least 0.8 g/g. Kidney assessment determines whether the indication applies.Kinpeygo contains budesonide in a formulation intended for primary IgA nephropathy in adults. EMA describes use when protein loss in urine is at least 1 g/day, or the urine protein-to-creatinine ratio is at least 0.8 g/g. Kidney assessment determines whether the indication applies.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Kinpeygo should I ask about?
Modified-release hard capsules containing 4 mg budesonide. This formulation is not interchangeable with every other budesonide product.Modified-release hard capsules containing 4 mg budesonide. This formulation is not interchangeable with every other budesonide product.
Read the primary sourceWhat determines the price of Kinpeygo?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Kinpeygo?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.